CA2852518C - Azepanone compounds and their use for the inhibition of deubiquitinating activity and the treatment of cancer - Google Patents
Azepanone compounds and their use for the inhibition of deubiquitinating activity and the treatment of cancer Download PDFInfo
- Publication number
- CA2852518C CA2852518C CA2852518A CA2852518A CA2852518C CA 2852518 C CA2852518 C CA 2852518C CA 2852518 A CA2852518 A CA 2852518A CA 2852518 A CA2852518 A CA 2852518A CA 2852518 C CA2852518 C CA 2852518C
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- compound
- cancer
- bortezomib
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/08—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1100776 | 2011-10-19 | ||
| SE1100776-2 | 2011-10-19 | ||
| SE1200303 | 2012-05-16 | ||
| SE1200303-4 | 2012-05-16 | ||
| PCT/SE2012/000158 WO2013058691A1 (en) | 2011-10-19 | 2012-10-15 | Method for inhibition of deubiquitinating activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2852518A1 CA2852518A1 (en) | 2013-04-25 |
| CA2852518C true CA2852518C (en) | 2019-09-24 |
Family
ID=48141165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2852518A Active CA2852518C (en) | 2011-10-19 | 2012-10-15 | Azepanone compounds and their use for the inhibition of deubiquitinating activity and the treatment of cancer |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9221761B2 (https=) |
| EP (1) | EP2780326B1 (https=) |
| JP (1) | JP6165748B2 (https=) |
| KR (1) | KR102022575B1 (https=) |
| CN (1) | CN104271557B (https=) |
| AU (1) | AU2012326682B2 (https=) |
| BR (1) | BR112014009365B1 (https=) |
| CA (1) | CA2852518C (https=) |
| CL (1) | CL2014000998A1 (https=) |
| DK (1) | DK2780326T3 (https=) |
| EA (1) | EA026409B1 (https=) |
| ES (1) | ES2713484T3 (https=) |
| HU (1) | HUE041816T2 (https=) |
| IL (1) | IL232118A (https=) |
| MX (1) | MX345467B (https=) |
| MY (1) | MY169330A (https=) |
| PL (1) | PL2780326T3 (https=) |
| PT (1) | PT2780326T (https=) |
| SG (1) | SG11201401608PA (https=) |
| WO (1) | WO2013058691A1 (https=) |
| ZA (1) | ZA201403302B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201401608PA (en) * | 2011-10-19 | 2014-07-30 | Vivolux Ab | Method for inhibition of deubiquitinating activity |
| EP2938610A2 (en) | 2012-12-28 | 2015-11-04 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof |
| WO2016004221A1 (en) * | 2014-07-01 | 2016-01-07 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying and treating mammals resistant to proteasome inhibitor treatments |
| GB201416754D0 (en) * | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| CA2976741C (en) * | 2015-03-30 | 2023-01-17 | Mission Therapeutics Limited | 1-cyano-pyrrolidine compounds as usp30 inhibitors |
| CN106146542A (zh) * | 2015-04-23 | 2016-11-23 | 北京大学 | 姜黄素硼酸衍生物,其制备方法和应用 |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| US10416163B2 (en) * | 2016-02-26 | 2019-09-17 | Regents Of The University Of Minnesota | Method and treatment of recurring endometrial cancer with an inhibitor of USP14 |
| WO2018140907A1 (en) * | 2017-01-30 | 2018-08-02 | Up Therapeutics Inc. | Novel spiro and cyclic bis-benzylidine proteasome inhibitor for the treatment of cancer, diabetes and neurological disorders |
| US12539292B2 (en) | 2018-04-01 | 2026-02-03 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| CN111956804B (zh) * | 2020-07-21 | 2022-01-07 | 广州医科大学 | Otub1的抑制剂的新应用 |
| CN114959036A (zh) * | 2022-06-07 | 2022-08-30 | 北京大学 | Rpn11标记物在检测骨髓瘤及其患病风险、预后分析及治疗药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6664272B2 (en) * | 1999-12-03 | 2003-12-16 | Emory University | Curcumin analogs with anti-tumor and anti-angiogenic properties |
| EP1572078A4 (en) * | 2002-03-08 | 2006-08-09 | Univ Emory | NEW CURCUMINOID FACTOR VIIa CONSTRUCTS AS MEANS OF SUPPRESSING TUMOR GROWTH AND ANGIOGENESIS |
| WO2007007207A2 (en) * | 2005-04-13 | 2007-01-18 | Khairia Youssef | Pharmaceutical compositions of 3, 5 -bis (arylidene) -4 -piperidones and analogues there of for modulating cell proliferation |
| EP1749822B1 (en) * | 2005-08-05 | 2008-10-15 | Hybrigenics S.A. | Novel cysteine protease inhibitors and their therapeutic applications |
| US7582655B2 (en) * | 2005-11-22 | 2009-09-01 | University Of Saskatchewan | Antineoplastic compounds |
| WO2011005790A1 (en) * | 2009-07-06 | 2011-01-13 | The Ohio State University Research Foundation | Compositions and methods for inhibition of cancers |
| SG11201401608PA (en) * | 2011-10-19 | 2014-07-30 | Vivolux Ab | Method for inhibition of deubiquitinating activity |
-
2012
- 2012-10-15 SG SG11201401608PA patent/SG11201401608PA/en unknown
- 2012-10-15 ES ES12841677T patent/ES2713484T3/es active Active
- 2012-10-15 WO PCT/SE2012/000158 patent/WO2013058691A1/en not_active Ceased
- 2012-10-15 MY MYPI2014001125A patent/MY169330A/en unknown
- 2012-10-15 DK DK12841677.3T patent/DK2780326T3/en active
- 2012-10-15 EA EA201490800A patent/EA026409B1/ru not_active IP Right Cessation
- 2012-10-15 PL PL12841677T patent/PL2780326T3/pl unknown
- 2012-10-15 EP EP12841677.3A patent/EP2780326B1/en active Active
- 2012-10-15 AU AU2012326682A patent/AU2012326682B2/en not_active Ceased
- 2012-10-15 MX MX2014004646A patent/MX345467B/es active IP Right Grant
- 2012-10-15 BR BR112014009365-2A patent/BR112014009365B1/pt not_active IP Right Cessation
- 2012-10-15 KR KR1020147012947A patent/KR102022575B1/ko not_active Expired - Fee Related
- 2012-10-15 CN CN201280062713.XA patent/CN104271557B/zh not_active Expired - Fee Related
- 2012-10-15 HU HUE12841677A patent/HUE041816T2/hu unknown
- 2012-10-15 PT PT12841677T patent/PT2780326T/pt unknown
- 2012-10-15 JP JP2014537023A patent/JP6165748B2/ja not_active Expired - Fee Related
- 2012-10-15 CA CA2852518A patent/CA2852518C/en active Active
-
2014
- 2014-04-13 IL IL232118A patent/IL232118A/en active IP Right Grant
- 2014-04-17 CL CL2014000998A patent/CL2014000998A1/es unknown
- 2014-04-18 US US14/256,280 patent/US9221761B2/en not_active Expired - Fee Related
- 2014-05-08 ZA ZA2014/03302A patent/ZA201403302B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2852518C (en) | Azepanone compounds and their use for the inhibition of deubiquitinating activity and the treatment of cancer | |
| Chen et al. | Strategies of targeting CK2 in drug discovery: challenges, opportunities, and emerging prospects | |
| Blackburn et al. | Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform | |
| Liang et al. | Structure, functions and selective inhibitors of HDAC6 | |
| Sosič et al. | Cathepsin B inhibitors: Further exploration of the nitroxoline core | |
| US9896420B2 (en) | N-quinolin-benzensulfonamides and related compounds for the treatment of cancer, autoimmune disorders and inflammation | |
| Blaquiere et al. | Medicinal chemistry of inhibiting RING-type E3 ubiquitin ligases | |
| JP2017528448A (ja) | プロタンパク質コンバターゼであるスブチリシン／ケキシンタイプ９（ｐｃｓｋ９）のタンパク質活性のモジュレーションのための、結合リガンドとしての小分子の組成物およびその使用方法 | |
| Sharma et al. | Enhancement of Chemotherapeutic Efficacy by Small Molecule Inhibition of NF-κ B and Checkpoint Kinases | |
| Karle et al. | Discovery of benzothiazole guanidines as novel inhibitors of thrombin and trypsin IV | |
| Tasneem et al. | Heterocyclic moieties as HDAC inhibitors: role in cancer therapeutics | |
| Zhang et al. | MALT1 inhibitors and degraders: strategies for NF-κB-driven malignancies | |
| US20130079370A1 (en) | Method for the Inhibition of Deubiquitinating Activity | |
| Ammann et al. | Discovery of edecesertib (GS-5718): a potent, selective inhibitor of IRAK4 | |
| Xu et al. | Recent advances in the development of Rho kinase inhibitors (2015–2021) | |
| Bano et al. | A review on cullin neddylation and strategies to identify its inhibitors for cancer therapy | |
| US20140370528A1 (en) | Proteasome Deubiquinating Inhibitor Screening | |
| SE1200735A1 (sv) | Sätt att inhibera deubiqutineringsaktivitet | |
| Li et al. | Development of novel PRMT7 inhibitors for the treatment of prostate cancer | |
| HK1203194B (en) | Method for inhibition of deubiquitinating activity | |
| NZ624019B2 (en) | Method for inhibition of deubiquitinating activity | |
| Sgorbissa et al. | Isopeptidases in anticancer therapy: looking for inhibitors | |
| CN114920728B (zh) | 一种甲异靛衍生物及其制备方法与应用 | |
| WO2008095296A1 (en) | Class ii histone deacetylase whole cell enzyme assay | |
| Hillert | Mechanistic studies of a novel inhibitor of the ubiquitin-proteasome system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20171012 |
|
| H11 | Ip right ceased following rejected request for revival |
Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED Effective date: 20250416 |